Table 1.
Characteristics of the study group.
| Variable | Values |
|---|---|
| Age [years], mean ± SD | 40.55 ± 9.04 |
| Disease duration [years], mean ± SD | 12.43 ± 7.01 |
| Sex, n (%) | |
| Female | 73 (72.3) |
| Male | 28 (27.7) |
| Education, n (%) | |
| Vocational education | 10 (9.9) |
| Secondary education | 34 (33.7) |
| Higher education | 57 (56.4) |
| Place of residence, n (%) | |
| Village | 22 (21.8) |
| City | 79 (78.2) |
| Marital status, n (%) | |
| Single | 35 (34.7) |
| Married | 51 (50.5) |
| Divorced | 15 (14.9) |
| Professional activity, n (%) | |
| Study | 4 (4.0) |
| Employed | 77 (76.2) |
| Disability or retirement pension | 19 (18.8) |
| Unemployed | 1 (1.0) |
| Clinical type of MS, n (%) | |
| RRMS | 101 (100) |
| SPMS | 0 (0) |
| PPMS | 0 (0) |
| PRMS | 0 (0) |
| Using DMT, n (%) | |
| Yes | 101 (100) |
| No | 0 (0) |
| Type of DMT, n (%) | |
| Dimethyl fumarate | 37 (36.6) |
| Ofatumumab | 22 (21.8) |
| Ocrelizumab | 10 (9.9) |
| Teriflunomide | 7 (6.9) |
| IFNb-1a | 7 (6.9) |
| IFNb-1b | 6 (5.9) |
| Glatiramer acetate | 4 (4.0) |
| Fingolimod | 3 (3.0) |
| Cladribine | 2 (2.0) |
| Natalizumab | 2 (2.0) |
| Ozanimod | 1 (1.0) |
| Comorbidities, n (%) | |
| Yes | 30 (29.7) |
| No | 71 (70.3) |
| Complains, n (%) | |
| Fatigability | 85 (84.2) |
| Dysphagia | 9 (8.9) |
| Speech disorders | 12 (11.9) |
| Hypertonia | 11 (10.9) |
| Mood disorders | 43 (42.5) |
| Paresthesia, neuralgia | 31 (30.7) |
| Mobility and balance disorders | 54 (53.5) |
| Sexual disorders | 37 (36.6) |
| Vision disorders | 54 (53.5) |
| Sphincter disorders | 32 (31.7) |
| MusiQoL total, mean ± SD | 69.33 ± 13.25 |
| LOT-R, mean ± SD | 14.29 ± 4.21 |
| IZZ, mean ± SD | 84.82 ± 10.33 |
| AIS, mean ± SD | 29.84 ± 7.10 |
| EDSS mean ± SD | 2.24 ± 1.2 |